Linezolida Hikma (Linezolid)

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This prevents formation of the initiation complex required for translation, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE.

The dosage of linezolid is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals set the appropriate regimen for each individual case.

Safety data for linezolid in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only recommended when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and necessary import documentation.

Linezolid offers oral and intravenous options and is active against many Gram‑positive organisms resistant to beta‑lactams and glycopeptides, such as MRSA and VRE. Compared with vancomycin, linezolid provides similar efficacy for many infections but may be preferred when renal impairment limits vancomycin use or when oral therapy is needed.

Linezolida Hikma should be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen or shaken. Maintain the cold‑chain during transport and handling to preserve product stability.

Linezolida Hikma is supplied as an injectable solution for intravenous administration. It is typically infused over a specified period as directed by the prescriber, using aseptic technique and appropriate infusion equipment in a clinical setting.

Serious risks include myelosuppression (especially thrombocytopenia and anemia), peripheral and optic neuropathy, serotonin syndrome when combined with serotonergic agents, and rare metabolic disturbances such as lactic acidosis. Patients should be monitored regularly for hematologic changes and neurological symptoms.

Linezolida Hikma should be avoided in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking serotonergic medications, those with pre‑existing severe myelosuppression, and patients with uncontrolled hypertension when combined with tyramine‑rich foods.